MSL 109 humanized monoclonal antibody: Began Phase II double-blind, randomized trial in 168 patients who will receive seven doses of placebo or 15 or 60 mg of d

Protein Design Labs Inc. (PDLI), Mountain View, Calif. Product: MSL 109 humanized monoclonal antibody Indication: Cytomegalovirus (CMV) infection after bone marrow transplant Status: Began Phase II do...